(HealthDay)—Chemotherapy-free induction and consolidation first-line treatment with dasatinib and blinatumomab is associated with a high incidence of molecular response and survival in adults with Philadelphia
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok
